Actively Recruiting

Phase 2
Age: 55Years - 70Years
All Genders
NCT07220473

Tirzepatide to Slow Biological Aging

Led by The University of Texas Medical Branch, Galveston · Updated on 2026-03-24

90

Participants Needed

1

Research Sites

96 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg subcutaneously (SC) weekly or no drug for 24 weeks, followed by 12 weeks off the drug. Since tirzepatide is already recognized as a highly effective weight-loss agent in this population, the primary focus will not be on measuring weight loss. Instead, the study will document the effects of tirzepatide on markers of aging, physical function, and overall health.

CONDITIONS

Official Title

Tirzepatide to Slow Biological Aging

Who Can Participate

Age: 55Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 55-70 years
  • BMI 63 30 kg/m�b2 or 63 27 kg/m�b2 with at least one weight-related health condition
  • Stable use of anti-inflammatory, blood pressure, lipid, or glucose-lowering medications with no dose changes for at least 12 weeks prior and none planned during the study
  • Willing and able to provide written informed consent and complete all study procedures
Not Eligible

You will not qualify if you...

  • BMI greater than 35 kg/m�b2
  • Uncontrolled or end-stage cardiometabolic disease as judged by the investigator
  • Significant neurocognitive impairment as judged by the investigator
  • Current or planned use of obesity treatments or medications likely to cause significant weight changes during the study
  • Use of insulin
  • Plans to begin formal, intensive physical activity or specific diet programs during the study
  • Active eating disorder
  • Use or recent use of human growth hormone, tesamorelin, supraphysiologic testosterone or estradiol, or anabolic steroids unless stable for over 24 weeks
  • Active, severe delayed gastric emptying
  • Prior or planned major gastric surgery or bariatric surgery during the study
  • Known diabetic retinopathy
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
  • Untreated or poorly controlled thyroid disease
  • History of chronic pancreatitis
  • History or active suicidal ideation as judged by the investigator
  • Known allergy or sensitivity to GLP-1RA or GIPRA
  • Use or planned use of immunomodulatory or investigational therapies during the study
  • Any other medical condition posing increased risk for participation as judged by the investigator
  • Pregnancy, nursing, or plans for either during the study period

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Texas Medical Branch

Galveston, Texas, United States, 77555

Actively Recruiting

Loading map...

Research Team

L

Lamonne Crutcher

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here